Fondo Bibliografico Internacional Julio 2003
Ascitis y transtornos de la función renal.
The evolution of ascitic fluid analysis in the diagnosis
of spontaneous bacterial peritonitis. Runyon BA. American Journal of Gastroenterology
2003;98:1675-7.
Editorial.
Nitric oxide inhibition in cirrhosis and ascites. Cardenas
A. American Journal of Gastroenterology 2003;98:1666-7.
Carta.
Plasma volume expansion by albumin in cirrhosis. Relation
to blood volume distribution, arterial compliance and severity of disease.
Brinch K, Moller S, Bendtsen F, Becker U, Henriksen JH. Journal of Hepatology
2003;39:24-31.
La infusion de albúmina no expande la volemia
en pacientes con cirrosis avanzada.
Increased urinary excretion of aquaporin 2 in patients with
liver cirrhosis. P Ivarsen, J Frøkiær, N K Aagaard, et al. Gut
2003; 52: 1194-1199.
Aumento de la excreción urinaria de aquaporina
2 en pacientes cirróticos.
Octreotide in hepatorenal syndrome: A randomized, double-blind,
placebo-controlled, crossover study. Gilles Pomier-Layrargues, Sarto C. Paquin,
Ziad Hassoun, et al. Hepatology 2003;38:238-243.
El tratamiento con octeotride y albúmina no
revierte el síndrome hepatorrenal.
The management of ascites in cirrhosis: Report on the consensus
conference of the International Ascites Club. Kevin P. Moore, Florence Wong,
Pere Ginès, et al. Hepatology 2003;38:258-266.
Documento de consenso.
Increased carbon monoxide production in patients with cirrhosis
with and without spontaneous bacterial peritonitis. Dara De Las Heras, Javier
Fernández, Pere Ginès, et al. Hepatology 2003;38: 452-459.
Implicación del monóxido de carbono
(molécula vasodilatadora) en la patogenia de la disfunción circulatoria
del paciente cirrótico.
Spironolactone alone or in combination with furosemide in
the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative
study of efficacy and safety. Santos J, Planas R, Pardo A, Durandez R, Cabre
E, Morillas RM, Granada ML, Jimenez JA, Quintero E, Gassull MA. Journal of
Hepatology 2003;39:187-92.
Para el tratamiento de la ascitis moderada puede
ser suficiente utilizar espironolactona sin furosemida.
